@sevenworldscollide.bsky.socialOn #WorldEBHCDay I’d like to remind #EvidenceSynthesis researchers and funders of the importance of patient and public engagement. Here’s a FREE handy framework and learning to support researchers www.cochrane.org/learn/course...
@abangelabs.bsky.socialEuropean HTA harmonisation does not eliminate national evidence needs—strong launch plans must account for both layers. https://www.mattheneus.com/editorial/eu-hta-harmonisation-national-evidence-plans-2026-10-15 #HTA #EvidenceSynthesis #RegulatoryAffairs
@abangelabs.bsky.socialHealth-data access delays are not just operational friction—they belong in the validity plan. #HTA #EvidenceSynthesis #RegulatoryAffairs https://www.mattheneus.com/editorial/iqwig-gedig-health-data-access-validity-plan-2026-10-13
@abangelabs.bsky.socialScotland’s deuruxolitinib decision shows how indirect evidence can support class-comparator parity in severe alopecia. https://www.mattheneus.com/editorial/smc-deuruxolitinib-leqselvi-severe-alopecia-itc-comparable-efficacy-2026-10-12 #HTA #MAIC #EvidenceSynthesis
@abangelabs.bsky.socialRandom walks reveal how uncertainty moves through a network meta-analysis—and where variance diagnostics can expose weak links.
https://www.mattheneus.com/editorial/network-meta-analysis-diffusion-random-walk-variance-diagnostics-2026-10-15
#HTA #NMA #EvidenceSynthesis
@abangelabs.bsky.socialWhen the comparator bridge fails, added benefit can remain unproven—even with active-treatment evidence. https://www.mattheneus.com/editorial/g-ba-iqwig-benralizumab-hes-mepolizumab-indirect-comparison-infeasible-2026-10-15 #HTA #NMA #EvidenceSynthesis #RegulatoryAffairs
@abangelabs.bsky.socialIron deficiency may shift HbA1c enough to distort evidence thresholds. #HTA #EvidenceSynthesis #HealthEconomics https://www.mattheneus.com/editorial/biochemia-medica-iron-deficiency-hba1c-false-elevation-meta-analysis-2026-10-15
@abangelabs.bsky.socialThree trials, no head-to-head: a network meta-analysis compares neoadjuvant bladder-cancer strategies. #HTA #NMA #EvidenceSynthesis https://www.mattheneus.com/editorial/pubmed-bladder-cancer-neoadjuvant-ddmvac-durvalumab-network-meta-analysis-2026-10-15
@abangelabs.bsky.socialHPV vaccine cost-effectiveness evidence doesn’t travel unchanged.
https://www.mattheneus.com/editorial/hpv-vaccination-economic-evaluation-transferability-price-threshold-screening-context-2026-10-14
#HTA #HealthEconomics #EvidenceSynthesis
@abangelabs.bsky.socialCase-only evidence and high cost proved insufficient for targeted import funding in Poland. #HTA #EvidenceSynthesis #RegulatoryAffairs https://www.mattheneus.com/editorial/aotmit-xuriden-dee50-targeted-import-case-series-cost-rejection-2026-09-30
@abangelabs.bsky.socialHospital screening can look cost-saving—until one fragile effectiveness assumption moves. #HTA #HealthEconomics #EvidenceSynthesis https://www.mattheneus.com/editorial/carbapenemase-screening-effectiveness-cost-saving-transferability-2026-10-13
@abangelabs.bsky.socialScotland accepts atogepant for acute migraine after an indirect class comparison—what the Bayesian network evidence means for HTA decisions. https://www.mattheneus.com/editorial/smc-atogepant-aquipta-acute-migraine-bayesian-network-comparison-2026-10-12 #HTA #NMA #EvidenceSynthesis #Pharma
@abangelabs.bsky.socialAutomated evidence retrieval is moving from promise to methodological scrutiny in German HTA. https://www.mattheneus.com/editorial/iqwig-ga2605-search-source-screening-methods-2026-10-13 #HTA #EvidenceSynthesis #RegulatoryAffairs
@abangelabs.bsky.socialA mortality signal is not yet an implementation case: what payers still need from convective dialysis evidence. #HTA #EvidenceSynthesis #HealthEconomics https://www.mattheneus.com/editorial/cochrane-convective-dialysis-mortality-signal-implementation-evidence-2026-10-13
@abangelabs.bsky.socialTop-ranked doesn’t mean decision-ready: why transfusion-threshold evidence in acute brain injury still needs an audit. https://www.mattheneus.com/editorial/acute-brain-injury-transfusion-threshold-bayesian-nma-evidence-audit-2026-10-12 #HTA #NMA #EvidenceSynthesis
@worldebhcday.bsky.socialRead the #WorldEBHCDay blog by Hailey Wills, Evidence Synthesis Coordinator at the Maritime SPOR SUPPORT Unit, who discusses the importance of having humans at the centre of comprehensive searches for #EvidenceSynthesis projects when using #AI tools.
Read blog: https://ow.ly/OQOi50ZVcmK
@abangelabs.bsky.socialWhy did Germany find aficamten’s added benefit unproven against mavacamten? Endpoint choice and indirect-comparison limits matter. https://www.mattheneus.com/editorial/iqwig-aficamten-obstructive-hcm-mavacamten-endpoint-itc-nonproof-2026-08-27 #HTA #MAIC #EvidenceSynthesis
@abangelabs.bsky.socialElahere’s direct survival evidence still leaves adjusted-comparison uncertainty where decision-makers need clarity. https://www.mattheneus.com/editorial/smc-elahere-mirvetuximab-mirasol-maic-survival-model-2026-10-12 #HTA #MAIC #EvidenceSynthesis #Pharma
@abangelabs.bsky.socialIn type 3 von Willebrand disease, bleeding-rate assumptions can decide whether prophylaxis looks cost-saving. https://www.mattheneus.com/editorial/type-3-von-willebrand-prophylaxis-cost-saving-bleeding-rate-assumptions-2026-10-13 #HTA #HealthEconomics #EvidenceSynthesis
@cochrane.orgA new Cochrane review finds that existing evidence is too uncertain to determine whether medical cannabis improves sleep or daytime functioning in people with insomnia.
